ARK Investment Management - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.

Quarter-by-quarter ownership
ARK Investment Management ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$325,133,913
-21.1%
7,163,118
-2.4%
2.49%
-8.8%
Q2 2023$411,980,394
+14.0%
7,338,447
-8.2%
2.73%
+9.8%
Q1 2023$361,396,203
+13.5%
7,990,188
+2.0%
2.48%
-9.9%
Q4 2022$318,286,736
-40.9%
7,829,932
-5.0%
2.76%
-26.5%
Q3 2022$538,381,000
-4.7%
8,238,422
-15.3%
3.75%
+12.4%
Q2 2022$564,758,000
-4.3%
9,728,831
+3.4%
3.34%
+35.5%
Q1 2022$590,376,000
-14.3%
9,405,371
+3.5%
2.46%
+18.3%
Q4 2021$688,778,000
-18.9%
9,089,168
+19.8%
2.08%
+2.1%
Q3 2021$849,064,000
-32.6%
7,585,674
-2.4%
2.04%
-13.0%
Q2 2021$1,258,876,000
+24.6%
7,776,119
-6.2%
2.34%
+16.7%
Q1 2021$1,010,179,000
-36.6%
8,290,350
-20.4%
2.01%
-52.7%
Q4 2020$1,594,331,000
+125.4%
10,412,976
+23.1%
4.24%
+1.1%
Q3 2020$707,370,000
+48.5%
8,457,320
+30.4%
4.20%
-18.1%
Q2 2020$476,454,000
+162.1%
6,483,251
+51.3%
5.12%
+13.1%
Q1 2020$181,754,000
+0.9%
4,285,632
+44.9%
4.53%
-0.3%
Q4 2019$180,074,000
+57.9%
2,956,635
+6.3%
4.54%
+82.5%
Q3 2019$114,040,000
-11.1%
2,782,140
+2.1%
2.49%
-23.0%
Q2 2019$128,317,000
+77.6%
2,724,349
+34.7%
3.23%
+56.6%
Q1 2019$72,262,000
+90.9%
2,023,017
+52.7%
2.06%
+34.4%
Q4 2018$37,858,000
-41.3%
1,325,110
-8.8%
1.54%
-21.1%
Q3 2018$64,467,000
+134.9%
1,453,590
+211.2%
1.95%
+93.6%
Q2 2018$27,449,000
+727.8%
467,140
+544.0%
1.01%
+509.7%
Q1 2018$3,316,000
+349.9%
72,534
+131.1%
0.16%
+179.7%
Q4 2017$737,000
+257.8%
31,388
+143.5%
0.06%
+47.5%
Q2 2017$206,00012,8880.04%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2020
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders